PRKCD and cancer: In recent years, PKCδ-involved signaling pathways have been considered as targets of several novel anti-cancer agents and the ability of PKC activators to induce apoptosis in a wide range of leukemia-derived cell lines has made them attractive targets for the development of anti-leukemic drugs [5,6].